GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » Revenue

Cyfuse Biomedical KK (TSE:4892) Revenue : 円61.11 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK Revenue?

Cyfuse Biomedical KK's revenue for the three months ended in Dec. 2023 was 円31.38 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was 円61.11 Mil. Cyfuse Biomedical KK's Revenue per Share for the three months ended in Dec. 2023 was 円3.98. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was 円7.78.

Warning Sign:

Cyfuse Biomedical KK revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Cyfuse Biomedical KK was -94.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -25.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 4 years, Cyfuse Biomedical KK's highest 3-Year average Revenue per Share Growth Rate was -25.90% per year. The lowest was -25.90% per year. And the median was -25.90% per year.


Cyfuse Biomedical KK Revenue Historical Data

The historical data trend for Cyfuse Biomedical KK's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK Revenue Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Revenue
137.48 708.25 374.48 61.11

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only 33.72 7.07 11.20 11.46 31.38

Competitive Comparison of Cyfuse Biomedical KK's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Revenue distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Revenue falls into.



Cyfuse Biomedical KK Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円61.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyfuse Biomedical KK  (TSE:4892) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Cyfuse Biomedical KK Revenue Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK (TSE:4892) Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK (TSE:4892) Headlines

No Headlines